Af­ter Big Phar­ma sparked in­ter­est in the US, Ablaze looks to bring ra­dio­phar­ma­ceu­ti­cals over­seas

Thanks in part to in­ter­est from Big Phar­ma play­ers like Bay­er and No­var­tis over the last decade, there’s been no short­age in cash for new com­pa­nies look­ing to slay tu­mor cells with tar­get­ed ra­dioiso­topes. Now a transpa­cif­ic up­start has hooked $75 mil­lion to bring the in­creas­ing­ly pop­u­lar drugs to Chi­na.

Ablaze Phar­ma­ceu­ti­cals emerged from stealth on Mon­day with a Vi­vo Cap­i­tal and Ad­van­Tech Cap­i­tal-led Se­ries A round and a li­cens­ing pact with Ver­sant-backed Rayze­Bio. The goal? In­tro­duce tar­get­ed ra­dio­phar­ma­ceu­ti­cal ther­a­pies (TRTs) to the Chi­nese mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER